Mashup Score:7
OncLivePatient Profile 1: Resection for Early/Intermediate Stage HCC - 6 days
Mashup Score:7
Twitter Feed: OncLive.com
Mashup Score:7
OncLiveThe addition of abemaciclib to trastuzumab, with or without fulvestrant, provided a numerical overall survival improvement over standard-of-care trastuzumab plus chemotherapy in patients with...
-
Abemaciclib + trastuzumab, w/ or w/o fulvestrant, provided a numerical OS improvement over SOC trastuzumab + chemotherapy in patients w/ HR+, HER2-positive advanced breast cancer. #bcsm #ESMO2022 https://t.co/kcgCSpTKro https://t.co/kcgCSpTKro - view on twitter
Mashup Score:7
OncLiveImmunotherapy Drives First-line Systemic Treatment for Advanced HCC - 1 week
Mashup Score:7
Evidence-based decisions have leveraged the use of immunotherapy combination atezolizumab plus bevacizumab for patients who receive a diagnosis of hepatocellular...
-
Immunotherapy Drives First-line Systemic Treatment for Advanced HCC @GIcancerDoc @MayoClinic @DrElkhoueiry @KeckMedUSC @MarkYarchoan @hopkinskimmel @ArndtVogel #oncology https://t.co/2KKyLCHpip - view on twitter
More coverage:
#oncology
Mashup Score:6
OncLiveFDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion+ Solid Tumors - 1 week
Mashup Score:6
The FDA has granted accelerated approval to selpercatinib for adult patients with locally advanced or metastatic solid tumors harboring a RET gene fusion that...
-
BREAKING: @US_FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion+ Solid Tumors #oncology https://t.co/YS838aDhgx https://t.co/YS838aDhgx - view on twitter
More coverage:
#oncology
Mashup Score:6
OncLiveLurbinectedin Exhibits Encouraging Efficacy, Signaling Forward Momentum in SCLC Management - 3 days
Mashup Score:6
The field of relapsed/refractory small cell lung cancer is expanding to include novel options for disease management, most notably, the chemotherapy...
-
Lurbinectedin Exhibits Encouraging Efficacy, Signaling Forward Momentum in SCLC Management @DrSanjayPopat @royalmarsdenNHS #lcsm #oncology https://t.co/Q5ACxWAKJQ - view on twitter
Mashup Score:6
event.onclive.comSUMMARY – OncLive/Institutional Perspectives in Cancer/Breast Cancer/September 27, 2022/ET - 1 day
Mashup Score:6
OncLive® Institutional Perspectives in Cancer: Disease State, Month Day, Year. Oncology Webinar features research and clinical advances in...
-
Tonight at 6:30pm PT! Participate in the Breast Cancer #OncLiveIPC event with Joanne Mortimer, MD of @cityofhope Expert faculty @jwaismanMD Wade Smith, MD, Irene Morae Kang, MD, and Scott Glaser, MD. @OncLiveSOSS Register Today: https://t.co/SFyTiP6Fct https://t.co/SFyTiP6Fct - view on twitter
More coverage:
#oncliveipc
Mashup Score:5
event.onclive.comSUMMARY – OncLive/Institutional Perspectives in Cancer/Skin Cancer/September 20, 2022/CT - 1 week
Mashup Score:5
OncLive® Institutional Perspectives in Cancer: Disease State, Month Day, Year. Oncology Webinar features research and clinical advances in...
-
Tonight at 6:30pm CT! Participate in the Skin Cancer #OncLiveIPC event with @HTawbi_MD of @MDAndersonNews Expert faculty Michael A. Davies, MD, PhD, @MKWongMDPhD and @DrSapnaPatel @OncLiveSOSS Register Today: https://t.co/1VXgFbKGXj https://t.co/1VXgFbKGXj - view on twitter
More coverage:
#oncliveipc
June 17, 2022 | Aditya Bardia, MD, MPHVideo Player is loading.Current Time 0:00Duration 8:59Remaining Time 8:59Current Time 0:00Duration 0:00Remaining Time 0:00Video Player is loading.Current Time 0:00Duration 8:59Remaining Time 8:59Current...
-
WATCH: @dradityabardia, of @MGHCancerCenter, reviews recently published data from the EMERALD trial on elacestrant versus endocrine therapy in patients with ER-positive/HER2-negative breast cancer. #bcsm #oncology https://t.co/sRBkNpPN2b https://t.co/sRBkNpPN2b - view on twitter
Mashup Score:4
OncLiveAbemaciclib Plus Aromatase Inhibitor Generates Survival Benefit in HR+/HER2- Breast Cancer - 5 days
Mashup Score:4
The addition of abemaciclib to a nonsteroidal aromatase inhibitor elicited an improvement in overall survival vs a nonsteroidal aromatase inhibitor alone in patients with...
-
Abemaciclib + a nonsteroidal aromatase inhibitor elicited an improvement in overall survival vs a nonsteroidal aromatase inhibitor alone in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer. @MayoClinic #ESMO2022 #bcsm https://t.co/PqSKBsiDCC - view on twitter
Mashup Score:4
OncLivePembrolizumab plus chemoradiation failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation alone in patients with locally advanced head and neck...
-
Pembrolizumab + chemoradiation failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation alone in patients with locally advanced head and neck squamous cell carcinoma. #ESMO2022 #scmsm https://t.co/f5oZPNKlxi https://t.co/f5oZPNKlxi - view on twitter
Centering discussion on a patient with early/intermediate-stage HCC, expert panelists consider the roles of transplant, resection, and adjuvant therapy,...
Centering discussion on a pts w/ early/intermediate-stage HCC, experts consider the roles of transplant, resection, & adjuvant therapy. @GIcancerDoc @MayoClinic @DrElkhoueiry @uscnorris @pgholam @CWRUSOM @ArndtVogel @MarkYarchoan @HopkinsMedicine #oncology https://t.co/aanpvQXZp3 https://t.co/aanpvQXZp3 - view on twitter